High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice

Herrmann, Joerg; Lennon, Ryan J.; Barsness, Gregory W.; Sandhu, Gurpreet S.; Gulati, Rajiv; Best, Patricia J.M.; Sorajja, Paul; Bresnahan, John F.; Bell, Malcolm R.; Prasad, Abhiram

doi:10.1161/circinterventions.112.972182

Cited by 13 publications

(20 citation statements)

References 61 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Saadeddin et al 17 reported that, pre-procedural hsCRP elevation in 41.0% of patients with stable angina and who underwent PCI, and this was associated with a 2.27 fold higher risk of developing periprocedural myocardial injury. Herrmann et al 27 and Rhee et al 28 also described similar result in their studies. Ten percent of Group I and 4.0% of Group II had periprocedural myocardial injury in which CK-MB level was raised but less than five times of upper reference limit, or rise of CK-MB >5 times of upper reference limit without chest pain, ECG, echocardiographic changes.…”

Section: Discussionsupporting

confidence: 71%

“…27 In that study, atherosclerotic burden and disease activity that determine longterm clinical outcomes after PCI rather than inflammation per se. But Preprocedural hsCRP level seems to be a marker of baseline risk and is independently associated with the risk of periprocedural MI.…”

Section: Discussionmentioning

confidence: 99%

“…Findings does not support a role for routine measurement of hsCRP in the management of patients undergoing PCI in contemporary practice. 27 Racial, ethnic variation, more use of DES and Glycoprotein IIb/IIIa inhibitor might be responsible for this.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Association of Pre-procedural High Sensitivity C-Reactive Protein with In-hospital Outcome of Patients Undergoing Percutaneous Coronary Intervention

Jannat¹,

Akanda²,

Khalequzzaman³

et al. 2017

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

Emerging evidence links an elevated baseline inflammatory status to adverse outcome among patients undergoing percutaneous coronary intervention (PCI). Baseline inflammation measured by high sensitivity C-reactive protein hsCRP may prove useful for identification of high risk patients requiring adjunctive therapies. This prospective study was carried out in the department of cardiology, National Institute of Cardiovascular Diseases, Dhaka, during October 2012 to September 2013.Two hundred consecutive patients with CSA and UA undergoing PCI were included in the study. Study patients were divided into two groups on the basis of hsCRP levels. In Group I hsCRP levels were elevated, that is ≥3 mg/L and in Group II hsCRP levels were normal, that is < 3 mg/L, with 100 patients in each group. Following the procedure in-hospital outcome of study patients were observed. Increased incidence (44%) of adverse in-hospital outcome was found in Group I (44% Vs. 11%). Higher incidence of post procedural angina (17%), peri-procedural myocardial infarction (6%) and peri-procedural myocardial injury (10%) was observed in this group. Nonsignificant rate of acute myocardial infarction, significant arrhythmia, acute LVF, cardiogenic shock and death were found in elevated hsCRP Group. Overall Major Adverse Cardiac Events (6% Vs. 0%) were found in pre-procedural elevated hsCRP group. High sensitivity C-reactive protein remained independently predictive of adverse in-hospital outcome, with 95% CI of RR 1.4 -4.4 and p<001. The present study concludes that the hsCRP is an important and independent predictor of adverse in hospital outcome.

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of Pre-procedural High Sensitivity C-Reactive Protein with In-hospital Outcome of Patients Undergoing Percutaneous Coronary Intervention

Jannat¹,

Akanda²,

Khalequzzaman³

et al. 2017

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

show abstract

“…Given that the circulating level of CRP, considered currently considered to represent a "golden marker for inflammation", reflects the severity of inflammatory response and plays a significant role in the development of atherosclerosis, many studies have attempted to predict the future cardiovascular events and the response to therapy based on CRP-based risk classification (14,15). It has been proved that high levels of circulating CRP upon admission correlates with the extent of the infarction, the development of postinfarction heart failure and the presence of severe lesion by angiography, while in patients undergoing primary PCI, high CRP level before the procedure predicted the rate of early complications (16,17). In a previous study of Pietila et al, high serum C-reactive protein concentrations in acute myocardial infarction patients were found to predict an increased mortality up to 6 months following the infarction (18).…”

Section: Discussionmentioning

confidence: 99%

Correlations between severity of coronary atherosclerosis and persistent elevation of circulating C-reactive protein levels 30 days after an acute myocardial infarction

Benedek¹,

Beáta²,

Suciu³

et al. 2014

Romanian Review of Laboratory Medicine

View full text Add to dashboard Cite

“…Studies have shown that statins to treat high cholesterol could reduce the incidence of cardiovascular events after PCI . In previous studies, we demonstrated that Xuezhikang (an extract of Chinese red yeast rice whose main ingredient is lovastatin), especially large‐dose Xuezhikang, decreased serum levels of hs‐CRP, matrix metallopeptidase 9, and low‐density lipoprotein cholestero .…”

Section: Introductionmentioning

confidence: 85%

Rosuvastatin Reduces Ischemia‐Reperfusion Injury in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention

Jiang

Yang

Lin-chao

et al. 2014

Clinical Cardiology

View full text Add to dashboard Cite

Background: Statins reduce the incidence of cardiovascular events after percutaneous coronary intervention (PCI), but no clinical studies have investigated the role of statins in ischemia-reperfusion injury after PCI. Hypothesis: Rosuvastatin could reduce ischemia-reperfusion injury in patients with acute coronary syndrome treated with PCI. Objectives: We investigated the effects of rosuvastatin on ischemia-reperfusion injury in patients with acute coronary syndrome after PCI and evaluated short-term prognosis. Methods: Patients scheduled for emergent PCI were given either rosuvastatin for ≥6 months (10 mg/d, every night; n = 55) or no statins (control group; n = 65). Serum superoxide dismutase activity, malondialdehyde, brain natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hs-CRP) were determined before and after PCI, as well as left ventricular ejection fraction and left ventricular end-diastolic volume. Major adverse cardiac events were observed at follow-ups for 6 months. Results: Superoxide dismutase activity in the rosuvastatin-treated group was higher than that of the control group; serum levels of malondialdehyde were lower. BNP and hs-CRP levels in the rosuvastatin-treated group were lower than that of the control group. Four weeks after PCI, the left ventricular ejection fraction in the treatment group was higher than that of the control group, and the left ventricular end-diastolic volume was lower. At the 6-month follow-up, there was no difference in major adverse cardiac events between the 2 groups. Conclusions: Rosuvastatin before PCI reduced ischemia-reperfusion injury in patients with acute coronary syndrome, which suggests the importance of application of rosuvastatin before PCI for early intervention.

show abstract

High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice

Cited by 13 publications

References 61 publications

Association of Pre-procedural High Sensitivity C-Reactive Protein with In-hospital Outcome of Patients Undergoing Percutaneous Coronary Intervention

Association of Pre-procedural High Sensitivity C-Reactive Protein with In-hospital Outcome of Patients Undergoing Percutaneous Coronary Intervention

Correlations between severity of coronary atherosclerosis and persistent elevation of circulating C-reactive protein levels 30 days after an acute myocardial infarction

Rosuvastatin Reduces Ischemia‐Reperfusion Injury in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention

Contact Info

Product

Resources

About